Younossi, Zobair M. and Yu, Ming-Lung and Yilmaz, Yusuf and Alswat, Khalid Aida and Buti, Maria and Fernandez, Marlen Ivon Castellanos and Papatheodoridis, Georgios and Hamid, Saeed S. and El-Kassas, Mohamed and Chan, Wah Kheong and Duseja, Ajay K. and Gordon, Stuart C. and Eguchi, Yuichiro and Isakov, Vasily A. and Roberts, Stuart K. and Fan, Jian-Gao and Singal, Ashwani K. and Romero-Gomez, Manuel and Ahmed, Aijaz and Ong, Janus and Lam, Brian P. and Younossi, Issah and Nader, Fatema and Racila, Andrei and Stepanova, Maria and Alqahtani, Saleh (2023) Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry (TM). Journal of Viral Hepatitis, 30 (4). pp. 335-344. ISSN 1352-0504, DOI https://doi.org/10.1111/jvh.13800.
Full text not available from this repository.Abstract
Chronic hepatitis B (CHB) infection is one of the most common causes of cirrhosis and liver cancer worldwide. Our aim was to assess clinical and patient-reported outcome (PRO) profile of CHB patients from different regions of the world using the Global Liver Registry. The CHB patients seen in real-world practices are being enrolled in the Global Liver Registry. Clinical and PRO (FACIT-F, CLDQ, WPAI) data were collected and compared to baseline data from CHB controls from clinical trials. The study included 1818 HBV subjects (48 +/- 13 years, 58% male, 14% advanced fibrosis, 7% cirrhosis) from 15 countries in 6/7 Global Burden of Disease super-regions. The rates of advanced fibrosis varied (3-24%). The lowest PRO scores across multiple domains were in HBV subjects from the Middle East/North Africa (MENA), the highest - Southeast/East and South Asia. Subjects with advanced fibrosis had PRO impairment in 3 CLDQ domains, Activity of WPAI (p < 0.05). HBV subjects with superimposed fatty liver had more PRO impairments. In multivariate analysis adjusted for location, predictors of PRO impairment in CHB included female sex, advanced fibrosis, and non-hepatic comorbidities (p < 0.05). In comparison to Global Liver Registry patients, 242 controls from clinical trials had better PRO scores (Abdominal, Emotional, and Systemic scores of CLDQ, all domains of WPAI) (p < 0.05). In multivariate analysis with adjustment for location and clinicodemographic parameters, the associations of PROs with the enrollment setting (real-life Global Liver Registry vs. clinical trials) were no longer significant (all p > 0.10). The clinico-demographic portrait of CHB patients varies across regions of the world and enrollment settings. Advanced fibrosis and non-hepatic comorbidities are independently associated with PRO impairment in CHB patients.
| Item Type: | Article |
|---|---|
| Funders: | Center for Outcomes Research in Liver Diseases (COR-LD), Washington, DC, USA |
| Uncontrolled Keywords: | Emotional well-being; Fatigue; Fatty liver; Physical functioning; Viral hepatitis; Work productivity |
| Subjects: | Q Science > QR Microbiology > QR355 Virology R Medicine |
| Divisions: | Faculty of Medicine > Medicine Department |
| Depositing User: | Ms Zaharah Ramly |
| Date Deposited: | 27 Jun 2023 03:28 |
| Last Modified: | 27 Jun 2023 03:28 |
| URI: | http://eprints.um.edu.my/id/eprint/38844 |
Actions (login required)
 |
View Item |
